Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Cholecystitis

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease.

Clinical kidney journal·2020

Same author

Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.

Journal of the American Heart Association·2020

Same author

Funding kidney research as a public health priority: challenges and opportunities.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2020

Same author

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

The New England journal of medicine·2020

Same author

Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus.

Scientific reports·2020

Same author

Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.

International journal of molecular sciences·2020

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Statins, inflammation and kidney disease.

Vera Krane¹, Christoph Wanner

¹Department of Medicine 1, Division of Nephrology, University of Würzburg, Würzburg, Germany. wanner_c@medizin.uni-wuerzburg.de

Nature Reviews. Nephrology

|June 2, 2011

Summary

Statins, anti-inflammatory drugs, show limited benefit for cardiovascular events in chronic kidney disease (CKD) patients, even with high inflammation. Guidelines still recommend statins for early-stage CKD dyslipidemia.

Area of Science:

Nephrology
Cardiology
Pharmacology

Background:

Inflammation is common in chronic kidney disease (CKD) and linked to cardiovascular disease (CVD) risk.
Cardiovascular event rates escalate with worsening kidney function and acute-phase response activation.
Statins possess anti-inflammatory properties and are known to reduce cardiovascular event incidence.

Purpose of the Study:

To evaluate the efficacy of statin therapy in patients with chronic kidney disease (CKD), considering the role of inflammation.
To determine if statins offer cardiovascular benefits in CKD patients, particularly those with elevated inflammatory markers.

Main Methods:

Review of clinical trial data, including large randomized trials and meta-analyses.
Analysis of statin effects in CKD populations, with stratification based on inflammation levels (e.g., C-reactive protein).

Related Experiment Videos

Last Updated: Jun 1, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Consideration of the Study of Heart and Renal Protection (SHARP) trial findings.

Main Results:

Two large randomized trials in hemodialysis patients found no significant benefit of statin therapy on cardiovascular events, irrespective of inflammation.
Some data suggest potential kidney function protection with pravastatin in inflamed CKD individuals, but overall trial results were negative.
Despite lack of clear cardiovascular benefit in some CKD subgroups, guidelines support dyslipidemia treatment in early CKD stages.

Conclusions:

Statin therapy does not consistently demonstrate cardiovascular benefits in patients with chronic kidney disease (CKD), even in the presence of significant inflammation.
Current evidence does not support routine statin use solely for cardiovascular risk reduction in advanced CKD (e.g., hemodialysis patients).
Dyslipidemia management in early-stage CKD remains recommended, supported by broader trial and meta-analysis data.